123 related articles for article (PubMed ID: 37946551)
21. Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma.
Ogata D; Yanagisawa H; Suzuki K; Oashi K; Yamazaki N; Tsuchida T
Med Oncol; 2016 Oct; 33(10):116. PubMed ID: 27613162
[TBL] [Abstract][Full Text] [Related]
22. Electrochemotherapy for advanced cutaneous angiosarcoma: A European register-based cohort study from the International Network for Sharing Practices of electrochemotherapy (InspECT).
Campana LG; Kis E; Bottyán K; Orlando A; de Terlizzi F; Mitsala G; Careri R; Curatolo P; Snoj M; Sersa G; Valpione S; Quaglino P; Mowatt D; Brizio M; Schepler H
Int J Surg; 2019 Dec; 72():34-42. PubMed ID: 31618680
[TBL] [Abstract][Full Text] [Related]
23. Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Wagner MJ; Othus M; Patel SP; Ryan C; Sangal A; Powers B; Budd GT; Victor AI; Hsueh CT; Chugh R; Nair S; Leu KM; Agulnik M; Sharon E; Mayerson E; Plets M; Blanke C; Streicher H; Chae YK; Kurzrock R
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34380663
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion.
Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T
Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282
[TBL] [Abstract][Full Text] [Related]
25. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
[TBL] [Abstract][Full Text] [Related]
27. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.
Li J; Liu H; Li Y; Li J; Shen L; Long W; Yang C; Xu H; Xi W; Cai R; Feng W
Trials; 2022 Jan; 23(1):29. PubMed ID: 35012634
[TBL] [Abstract][Full Text] [Related]
28. A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.
Thomas M; Sadjadian P; Kollmeier J; Lowe J; Mattson P; Trout JR; Gargano M; Patchen ML; Walsh R; Beliveau M; Marier JF; Bose N; Gorden K; Schneller F
Invest New Drugs; 2017 Jun; 35(3):345-358. PubMed ID: 28303530
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological inhibition of PAI-1 alleviates cardiopulmonary pathologies induced by exposure to air pollutants PM
Ghosh AK; Soberanes S; Lux E; Shang M; Aillon RP; Eren M; Budinger GRS; Miyata T; Vaughan DE
Environ Pollut; 2021 Oct; 287():117283. PubMed ID: 34426376
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer.
Kato K; Chin K; Yoshikawa T; Yamaguchi K; Tsuji Y; Esaki T; Sakai K; Kimura M; Hamaguchi T; Shimada Y; Matsumura Y; Ikeda R
Invest New Drugs; 2012 Aug; 30(4):1621-7. PubMed ID: 21728023
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study.
Fujisawa Y; Fujimura T; Matsushita S; Yamamoto Y; Uchi H; Otsuka A; Funakoshi T; Miyagi T; Hata H; Gosho M; Kambayashi Y; Aoki M; Yanagi T; Ohira A; Nakamura Y; Maeda T; Yoshino K
Br J Dermatol; 2020 Nov; 183(5):831-839. PubMed ID: 32198756
[TBL] [Abstract][Full Text] [Related]
32. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
Takahashi N; Kameoka Y; Onizuka M; Onishi Y; Takahashi F; Dan T; Miyata T; Ando K; Harigae H
Cancer Med; 2023 Feb; 12(4):4250-4258. PubMed ID: 36151699
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.
Ray-Coquard IL; Domont J; Tresch-Bruneel E; Bompas E; Cassier PA; Mir O; Piperno-Neumann S; Italiano A; Chevreau C; Cupissol D; Bertucci F; Bay JO; Collard O; Saada-Bouzid E; Isambert N; Delcambre C; Clisant S; Le Cesne A; Blay JY; Penel N
J Clin Oncol; 2015 Sep; 33(25):2797-802. PubMed ID: 26215950
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous angiosarcoma treated with taxane-based chemoradiotherapy: A multicenter study of 90 Japanese cases.
Fujimura T; Furudate S; Maekawa T; Kato H; Ito T; Matsushita S; Yoshino K; Hashimoto A; Muto Y; Ohuchi K; Amagai R; Kambayashi Y; Fujisawa Y
Skin Health Dis; 2023 Feb; 3(1):e180. PubMed ID: 36751323
[TBL] [Abstract][Full Text] [Related]
35. Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study.
Fujisawa Y; Yoshino K; Kadono T; Miyagawa T; Nakamura Y; Fujimoto M
Br J Dermatol; 2014 Dec; 171(6):1493-500. PubMed ID: 24814962
[TBL] [Abstract][Full Text] [Related]
36. TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia.
Sasaki K; Fujiwara T; Ochi T; Ono K; Kato H; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Miyata T; Harigae H
Tohoku J Exp Med; 2022 Jun; 257(3):211-224. PubMed ID: 35491124
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group.
Schlemmer M; Reichardt P; Verweij J; Hartmann JT; Judson I; Thyss A; Hogendoorn PC; Marreaud S; Van Glabbeke M; Blay JY
Eur J Cancer; 2008 Nov; 44(16):2433-6. PubMed ID: 18771914
[TBL] [Abstract][Full Text] [Related]
38. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
Asao T; Shukuya T; Mimori T; Goto Y; Tanaka H; Takayama K; Tsubata Y; Tachihara M; Suzuki T; Kaira K; Ko R; Zenke Y; Akamatsu H; Tanizaki J; Ikeda S; Sugawara S; Mizutani H; Mori K; Takahashi K
Clin Lung Cancer; 2023 Nov; 24(7):e247-e253. PubMed ID: 37316381
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
[TBL] [Abstract][Full Text] [Related]
40. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
Shimomura O; Endo M; Makishima H; Yamada T; Hashimoto S; Numajiri H; Miyazaki Y; Doi M; Furuya K; Takahashi K; Moriwaki T; Hasegawa N; Yamamoto Y; Niisato Y; Kobayashi M; Mizumoto M; Nakai K; Saito T; Hoshiai S; Saida T; Mathis BJ; Mori K; Nakajima T; Tsuchiya K; Sakurai H; Oda T
BMC Cancer; 2023 Jul; 23(1):624. PubMed ID: 37403011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
